Review article: Helicobacter pylori eradication–understandable caution but no excuse for inertia

Alimentary Pharmacology & Therapeutics

Volumn 8, Issue 4, 1994, Pages 369-389

  PENSTON, J G ^a  

^a Ninewelk Hospital ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC THERAPY; CANDIDIASIS; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG MIXTURE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PATIENT COMPLIANCE; RECURRENT PEPTIC ULCER; REINFECTION; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING;

ANTIBIOTICS; ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; OMEPRAZOLE; PATIENT COMPLIANCE; PEPTIC ULCER; RECURRENCE;

EID: 0028001018     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1994.tb00304.x     Document Type: Article

References (180)

1. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families
2. Epidemiology of peptic ulcer disease
3. A prospective study of risk for peptic ulcer disease in Seventh‐Day Adventists
4. The incidence of duodenal ulcer in Copenhagen County
5. The incidence of gastric ulcer in Copenhagen County
6. Incidence of peptic ulcer disease in Gothenburg, 1985
7. Changing pattern of admissions and operations for duodenal ulcer
8. Epidemiology and course of gastrointestinal haemorrhage in North‐East Scotland
9. Upper gastrointestinal bleeding
10. Upper gastrointestinal bleeding in relation to previous use of analgesics and non‐steroidal anti‐inflammatory drugs
11. Changed profile of peptic ulcer disease in hospital patients during 1969–1984 in Finland
12. 2‐receptor antagonists
13. Health and economic aspects of peptic ulcer disease
14. Pharmaco‐economic consideration in the long‐term management of peptic ulcer disease
15. Triple therapy after duodenal ulcer healing with omeprazole or ranitidine eradicates H. pylori and prevents ulcer relapses: preliminary results of a year follow‐up study
16. Antibacterial treatment of gastric ulcers
17. Short and long‐term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone
18. Relationship between eradication of Helicobacter pylori and duodenal ulcer relapse after three different therapies: long‐term follow‐up
19. Recurrence of duodenal ulcers and Campylobacter pylori infection after eradication
20. Possibilities for Helicobacter pylori suppression/eradication
21. H. pylori eradication, side effects, compliance: 14 days versus 12 days triple therapy
22. Helicobacter pylori eradication with doxycycline‐metronidazole‐bismuth subsalicylate triple therapy
23. Short and medium‐term results of oral triple therapy to eradicate Campylobacter pylori
24. Four days triple drug therapies are not satisfactory for eradication of Helicobacter pylori
25. Evaluation of various multidrug regimens for Helicobacter pylori
26. Two‐week combination therapies with tetracycline are less effective than similar regimens with amoxycillin
27. High eradication rates can be achieved for H. pylori infection in just seven days
28. Optimum combination chemotherapy for H. pylori–fine tuning the ingredients
29. Eradication of Helicobacter pylori and duodenal ulcer relapse–a comparison of one‐week regimen and two‐week regimen
30. Omeprazole and colloidal bismuth subcitrate +/– adjuvant antibiotics in the treatment of Helicobacter pylori associated duodenal ulcer disease
31. Schubert T T
32. Helicobacter pylori treatment: one week double versus triple therapy: who needs bismuth
33. Resolution of Helicobacter associated gastritis after oral therapy in patients with non‐ulcer dyspepsia
34. Triple therapy is better than double in eradication of Helicobacter pylori
35. Helicobacter pylori: one week versus two weeks therapy
36. Cure of duodenal ulcer after eradication of Helicobacter pylori
37. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing
38. Helicobacter pylori gastritis and response to treatment
39. Treatment of H. pylori reduces the rate of rebleeding in complicated peptic ulcer disease
40. Duodenal ulcers heal without acid suppression if Helicobacter pylori is eradicated–a randomized trial
41. Randomized controlled trial of short‐term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer
42. Comparison of 3, 5 and 7 day triple therapy for Helicobacter pylori eradication
43. Amoxycillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized and controlled study
44. Helicobacter pylori therapy: randomized study of Denol/antibiotic combinations
45. Metronidazole resistance significantly affects eradication of H
46. A three‐day eradication regimen for Helicobacter pylori
47. One week eradication regimen for Helicobacter pylori
48. ‘Triple therapy’ containing sucralfate eradicates H. pylori
49. Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer
50. A prospective study of Helicobacter pylori infection treatment in resistant duodenal ulcers
51. Two weeks bismuth; tetracycline; metronidazole versus ranitidine in treatment of duodenal ulcer and its recurrence
52. Therapy of Helicobacter pylori infection: clinical trials with double and triple pharmacological association
53. Effect of H. pylori eradication on peptic ulcer healing
54. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate
55. Eradicating Helicobacter pylori and symptoms of non‐ulcer dyspepsia
56. Short report: short‐term triple therapy for H
57. Cure of chronic dyspepsia with eradication of Helicobacter pylori infection
58. Triple therapy versus omeprazole in Helicobacter pylori duodenal ulcer patients. Randomized single‐blind trial
59. Results of treatment of duodenal ulcer disease co‐existing with infection of Helicobacter pylori
60. Eradication of Helicobacter pylori with four different regimens
61. Cure of duodenal ulcer associated with eradication of Helicobacter pylori
62. Antimicrobial therapy for Helicobacter pylori associated duodenal ulcer: a long‐term follow‐up study
63. Fritz P
64. Long‐term follow‐up and antibody response to treatment of patients with Helicobacter pylori
65. Evaluation of two different one‐day treatment schedules for eradication of Helicobacter pylori infection
66. Treatment of Helicobacter pylori infection: comparison of double versus triple therapy
67. tetracycline and metronidazole in the treatment of patients with ulcer disease and Helicobacter pylori
68. Disappearance of gastritis after eradication of Helicobacter pylori
69. Long‐term serological surveillance after treatment of Helicobacter pylori infection
70. The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection
71. Treatment of duodenal ulcers with bismuth subcitrate
72. Non‐absorbable bismuth (Roter) is as effective as DeNol in eradicating H
73. Gastric mucosal CD3/CD4 lymphocytes and antigen presenting cells before and after triple therapy for Helicobacter pylori
74. Clinical efficacy of triple therapy in Helicobacter pylori‐associated duodenal ulcer
75. Failure to eradicate Helicobacter pylori in patients with metronidazole‐resistant strains
76. Experience with ‘triple’anti‐Helicobacter pylori eradication therapy: side effects and the importance of testing the pre‐treatment bacterial isolate for metronidazole resistance
77. Relevance of in vitro metronidazole‐resistance to H. pylori eradication and eradication failure
78. Rationale for metronidazole sensitivity testing in the treatment of Helicobacter pylori infection
79. Should amoxycillin be taken before or after meals when prescribed with omeprazole for the eradication of Helicobacter pylori? A randomized, controlled trial
80. Modified combined omeprazole/amoxycillin treatment for eradication of Helicobacter pylori: a pilot study
81. Long‐term follow‐up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin
82. Helicobacter pylori eradiation in duodenal ulcer patients with combined high dose omeprazole and amoxycillin treatment
83. Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole‐resistant
84. Experience with omeprazole in combination with either amoxycillin or colloidal bismuth subcitrate in patients with metronidazole‐resistant Helicobacter pylori
85. Galenic formulations of amoxycillin/clavulanate and eradication of Helicobacter pylori in peptic ulcer patients: preliminary report
86. Omeprazole plus amoxycillin regimens for eradicating H. pylori
87. Duodenal ulcer Helicobacter pylori positive: first results of the association with omeprazole and amoxycillin
88. Combined omeprazole/antibiotic treatment for eradicating Helicobacter pylori in patients with duodenal ulcer: pilot studies
89. High dose omeprazole plus amoxycillin in the treatment of acute duodenal ulcer
90. The detection of Helicobacter pylori in patients on long‐term H2 antagonist treatment and the evaluation of eradication using standard triple therapy compared with omeprazole and amoxycillin: a study in a single general practice
91. Helicobacter pylori treatment: disappointing results with amoxycillin plus omeprazole
92. Efficacy of combination therapy of omeprazole with antibiotics in eradication of Helicobacter pylori
93. Effect of a short‐term therapy with omeprazole and amoxycillin on H. pylori eradication: ulcer healing and relapse in patients with peptic ulcer
94. Amoxycillin plus omeprazole: a simple and effective therapeutic regimen to eradicate Helicobacter pylori
95. Omeprazole plus amoxycillin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer disease
96. Omeprazole plus amoxycillin: efficacy of various treatment regimens to eradicate Helicobacter pylori
97. Amoxycillin plus omeprazole for eradication of Helicobacter pylori in duodenal ulcer disease
98. Omeprazole improves amoxycillin therapy directed towards Helicobacter pylori‐associated chronic gastritis
99. Omeprazole and amoxycillin suspension for Helicobacter pylori
100. An increasing dose of omeprazole combined with amoxycillin increases eradication rate of Helicobacter pylori
101. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study
102. Amoxycillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients
103. What treatment is best for gastric Helicobacter pylori infection
104. Two weeks triple therapy for Helicobacter pylori overcomes metronidazole resistance
105. Eradication of Campylobacter pylori infection with bismuth subsalicylate and antibiotic combinations
106. One‐day therapy for Helicobacter pylori eradication
107. Efficacy and tolerability of a short term, low dose triple therapy for eradication of Helicobacter pylori
108. Evaluation of two short term amoxycillin/tinidazole regimens for eradication of Helicobacter pylori
109. Amoxycillin/omeprazole or triple therapy for eradication of H. pylori in duodenal ulcer disease
110. Controlled study of omeprazole‐amoxycillin‐tinidazole versus ranitidine‐amoxycillin‐tinidazole in Helicobacter py/ori‐associated duodenal ulcers
111. DeNol or DeNol plus metronidazole in the treatment of Helicobacter pylori positive patients with non‐ulcer dyspepsia: symptomatic response and eradication rate
112. Helicobacter pylori and duodenal ulcer recurrence: a 12 months follow‐up study
113. One week therapy for Helicobacter pylori eradication: follow‐up study of a randomized trial at one year after treatment
114. Two different triple therapy regimens for Helicobacter pylori‐positive duodenal ulcers
115. Effect of ranitidine and amoxycillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer
116. Helicobacter pylori reinfection and clinical course of ulcer disease in the first year after amoxycillin/omeprazole treatment
117. Recurrence of Helicobacter pylori infection
118. Triple antimicrobial therapy for H. pylori eradication in children: long term follow‐up
119. Campylobacter pyloridis‐associated chronic active antral gastritis
120. The long‐term outcome of dyspeptic patients after Helicobacter pylori eradication
121. Long term follow‐up of C
122. One‐year relapse rate after H. pylori eradication with omeprazole plus antimicrobials
123. Helicobacter pylori: treatment with combinations of pivampicillin and TDB
124. Long term evaluation of anti‐Hclif obacter pylori treatment in duodenal ulcer: monotherapy versus combination therapy
125. Eradication of Helicobacter pylori reduces symptomless relapses of peptic ulcer disease
126. Efficacy of three type regimens of triple therapy with DeNol in the treatment of duodenal ulcer disease
127. Helicobacter pylori eradication prevents duodenal ulcer relapse
128. Prospective double‐blind trial of duodenal ulcer relapse after eradication of C. pylori
129. Helicobacter pylori and duodenal ulcer recurrence
130. Eradication of H. pylori prevents duodenal ulcer recurrence
131. Results of treatment with Helicobacter pylori infection on the recurrence of gastric or duodenal ulcers: a randomized, single‐blind, single centre study
132. One week eradication regime for H. pylori heals and prevents recurrence of duodenal ulcer
133. Two‐year follow‐up after antibacterial treatment of duodenal ulcers–Munich duodenal ulcer trial
134. Healing and recurrence of duodenal ulcers
135. Duodenal ulcer recurrence after treatment of Helicobacter pylori. Double‐blind randomized placebo‐controlled trial
136. Cure of duodenal ulcer: eradication of Helicobacter pylori versus maintenance of healing
137. Randomized study for antimicrobial treatment in 30 duodenal ulcer H. pylori positive patients: two year results
138. Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by cefixime
139. A double‐blind study to compare Denol tablets in combination with metronidazole versus DeNol tablets or ranitidine in combination with metronidazole placebo in the treatment of gastric ulcer
140. Long‐term therapy of duodenal ulcer disease
141. Consensus and chaos in the management of Helicobacter pylori
142. Acceptance and clinical implication of Helicobacter pylori theory in duodenal ulcer disease
143. Maintenance therapy in duodenal and gastric ulcer disease: survey of practice amongst British gastroenterologists
144. Helicobacter pylori and peptic ulcers: the present position
145. Efficacy of H. pylori eradication therapy in clinical practice
146. A decade of experience with long‐term continuous treatment of peptic ulcers with H2‐receptor antagonists
147. Helicobacter pylori, duodenitis and duodenal ulceration
148. Helicobacter pylori, gastric ulceration and the postoperative stomach
149. The prevalence of Helicobacter pylori and NSAID use in patients with severe upper gastrointestinal haemorrhage and their potential role in recurrence of ulcer bleeding
150. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection
151. Helicobacter pylori, symptoms and NSAIDs at the first episode of duodenal ulcer in 100 patients
152. Review article: maintenance treatment with H2‐receptor antagonists for peptic ulcer disease
153. Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease
154. A placebo‐ controlled investigation of duodenal ulcer recurrence after withdrawal of long‐term treatment with ranitidine
155. Cross‐national changes in the effects of peptic ulcer disease
156. Changes in peptic ulcer and gastritis/duodenitis in Great Britain, 1970–1985
157. Complications of peptic ulcer disease before and after the introduction of H2‐receptor antagonists
158. Trends in morbidity and mortality from peptic ulcer disease: Tayside versus Scotland